Dr. Lili Belcastro is a Senior Principal Scientist at Bristol-Myers Squibb. She joined the company in March 2021 as a subject matter expert (SME) in the Material Sciences group in Cell Therapy Development. She is responsible for the cell therapy ancillary and raw materials used in BMS’s cell therapy pipeline and the management of the development Material Sciences & Engineering group. Prior to joining BMS, Lili was an SME at Janssen R&D where she qualified raw materials used in cell and gene therapy manufacturing. Lili has over ten years of experience in preclinical and clinical cancer biology, cell and gene therapy product development, and method development working with a variety of complex biological molecules and small molecule inhibitors. Lili holds a PhD in cancer biology from a joint program with the University of the Sciences and The Wistar Institute in Philadelphia.